Pfizer’s RSV Vaccine Springs Another Surprise, This Time In Maternal Use

Could Seize Share From Sanofi - Analysts

 
• By Andrew McConaghie
Pregnant woman vaccine
Interim analysis of the Phase IIb study showed 85% efficacy against RSV infection for infants born to vaccinated mothers.

More from Business

More from Scrip